Definium Says Second Phase 3 DT120 Study in Generalized Anxiety Disorder Meets Goal

07:56 AM EDT, 09/14/2026 (MT Newswires) -- Definium Therapeutics (DFTX) said Monday its second phase 3 study of DT120 orally disintegrating tablet in generalized anxiety disorder met the primary and key secondary endpoints. The company said its experimental lysergide formulation significantly improved anxiety symptoms versus placebo based on changes in the Hamilton Anxiety Rating Scale at week 12. Adult patients receiving 100 micrograms achieved a 9.8-point reduction in their Hamilton Anxiety Rating Scale score at week 12, compared with a 4.7-point reduction for those receiving placebo, the company said, adding that improvements were observed as early as day 2 and continued throughout the study. The experimental drug was generally well tolerated, with a safety profile consistent with prior clinical experience, the company said. Definium said it anticipates achieving alignment with the US Food and Drug Administration as it advances toward a new drug application submission. Shares of Definium Therapeutics were up more than 15% in premarket activity Monday.